A possible role for autoantibodies in left ventricular hypertrophy

Area of Science:

• Cardiology
• Immunology
• Pathophysiology

Background:

• Left-ventricular hypertrophy (LVH) is a significant cardiovascular condition.
• The role of autoimmune processes in LVH, particularly hypertrophic cardiomyopathy (HCM) and hypertension-induced LVH, requires further elucidation.

Purpose of the Study:

• To investigate the potential involvement of autoantibodies in the development and specific type of left-ventricular hypertrophy (LVH).
• To compare the incidence of autoantibodies in patients with HCM, essential hypertension, athletes, and healthy controls.

Main Methods:

• Echocardiography was used to assess cardiac performance indices, including LV mass and LV mass index.
• Indirect immunofluorescence was employed to detect autoantibodies against specific (anticardiac cell; ACA) and nonspecific (antimitochondrial cell; AMA) autoantigens.
• Complement levels (C3c and C4) were measured in ACA-positive and ACA-negative individuals.

Main Results:

• Patients with HCM exhibited higher LV mass and LV mass index compared to controls.
• A significantly higher incidence of both ACA and AMA was observed in patients with HCM and essential hypertension compared to athletes and controls.
• All ACA-positive individuals were also AMA-positive, and vice versa, indicating a strong association between these autoantibodies.
• ACA-positive individuals demonstrated elevated C3c and C4 complement levels.

Conclusions:

• The findings suggest a potential autoantibody-mediated immunopathogenic role in the development and type of myocardial hypertrophy.
• Autoantibodies, specifically ACA and AMA, may be implicated in the pathogenesis of HCM and hypertension-related LVH.